Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: A tissue microarray study of 284 cases and 18 markers

Journal of Pathology

Volumn 204, Issue 1, 2004, Pages 101-109

  Au, N H C ^a   Cheang, M ^a   Huntsman, D G ^a   Yorida, E ^a   Coldman, A ^b   Elliott, W M ^a   Bebb, G ^b   Flint, J ^a   English, J ^a   Gilks, C B ^a   Grimes, H L ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c University of Louisville School of Medicine   (United States)

Author keywords

Hierarchical clustering analysis; Non small cell lung cancer; Prognostic markers

Indexed keywords

BIOLOGICAL MARKER; BOMBESIN; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN; CYCLIN D1; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P63; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR E2F1; TUMOR MARKER; ZINC FINGER PROTEIN;

ARTICLE; CANCER STAGING; CLUSTER ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TUMOR; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; OUTCOMES RESEARCH; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MICROARRAY; SCORING SYSTEM; STATISTICAL ANALYSIS; VARIANCE; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLUSTER ANALYSIS; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 4544264923     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1612     Document Type: Article

References (58)

1. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988; 96: 440-447.
2. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29(1 Suppl 4): 3-14.
3. Maulik G, Kijima T, Salgia R. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med 2003; 74: 113-125.
4. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr. HER2/neu expression in malignant lung tumors. Semin Oncol 2002; 29(1 Suppl 4): 51-58.
5. Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001; 14: 556-562.
6. Bunn PA Jr, Helfrich B, Soriano AF, et al. Expression of Her2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001; 7: 3239-3250.
7. Schneider PM, Praeuer HW, Stoeltzing O, et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000; 83: 473-479.
8. Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 2002; 33: 105-110.
9. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98: 13 790-13 795.
10. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001; 98: 13 784-13 789.
11. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18: 705-719.
12. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 2001; 33(Suppl 1): S17-S24.
13. Minami K, Saito Y, Imamura H, Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002; 38: 51-57.
14. Dworakowska D, Gozdz S, Jassem E, et al. Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. Lung Cancer 2002; 35: 35-41.
15. Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 2001; 19: 555-561.
16. Kim YC, Park KO, Kern JA, et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998; 22: 181-190.
17. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992; 66: 735-738.
18. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994; 54: 2496-2503.
19. Isobe T, Hiyama K, Yoshida Y, Fujiwara Y, Yamakido M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res 1994; 85: 1240-1246.
20. Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol 2001; 25: 1204-1207.
21. Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002; 73: 403-405.
22. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarray for high-throughput molecular profiling of tumor specimens. Nature Med 1998; 4: 844-847.
23. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of inter-laboratory variation in the immunohistochemical determination of estrogen receptor using a breast cancer tissue microarray. Am J Clin Pathol 2002; 117: 723-728
24. Bremnes RM, Veve R, Gabrielson E, et al. High-thoughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002; 20: 2417-2428.
25. Hsu FD, Nielsen TO, Alkushi A, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 2002; 15: 1374-1380.
26. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002; 161: 1557-1565.
27. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95: 14 863-14 868.
28. Hirsch FR, Varella-Garcia M, Franklin WA, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002; 86: 1449-1456.
29. Hsieh CC, Chow KC, Fahn HJ, et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998; 66: 1159-1163.
30. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-1855.
31. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001; 19: 448-457.
32. Nacht M, Dracheva T, Gao Y, et al. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A 2001; 98: 15 203-15 208.
33. McDoniels-Silvers AL, Stoner GD, Lubet RA, You M. Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia 2002; 4: 141-150.
34. Volm M, Koomagi R, Efferth T, Mattern J. Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype. Anticancer Res 2002; 22: 2321-2324.
35. Brambilla E, Moro D, Gazzeri S, Brambilla C. Alterations of expression of Rb, p16 (INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188: 351-360.
36. Saitoh G, Sugio K, Ishida T, Sugimachi K. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. Oncol Rep 2001; 8: 737-743.
37. Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 2000; 82: 1747-1754.
38. Keum JS, Kong G, Yang SC, et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 1999; 81: 127-132.
39. Caputi M, Groeger AM, Esposito V, et al. Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am J Respir Cell Mol Biol 1999; 20: 746-750.
40. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001; 34: 207-218.
41. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin D1 and refinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997; 3: 1051-1058.
42. Anton RC, Coffey DM, Gondo MM, Stephenson MA, Brown RW, Cagle PT. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung. Mod Pathol 2000; 13: 1167-1172.
43. Nakamura H, Saji H, Ogata A, et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int J Cancer 2003; 103: 61-66.
44. Selvaggi G, Scagliotti GV, Torri V, et al. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer 2002; 94: 2669-2674.
45. Campling BG, el-Deiry WS. Clinical implications of p53 mutations in lung cancer. Methods Mol Med 2003; 75: 53-77.
46. Mao L. Molecular abnormalities in lung carcinogenesis and their potential clinical implications. Lung Cancer 2001; 34(Suppl 2): S27-S34.
47. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000; 6: 4055-4063.
48. Abbona G, Papotti M, Viberti L, Macri L, Stella A, Bussolati G. Chromogranin A gene expression in non-small cell lung carcinomas. J Pathol 1998; 186: 151-156.
49. Carnaghi C, Rimassa L, Garassino I, Santoro A. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. Ann Oncol 2001; 12(Suppl 2): S119-S123.
50. Said JW, Vimadalal S, Nash G, et al. Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors. Hum Pathol 1985; 16: 236-240.
51. Haimoto H, Takahashi Y, Koshikawa T, Nagura H, Kato K. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 1985; 52: 257-263.
52. Westerman BA, Neijenhuis S, Poutsma A, et al. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features. Clin Cancer Res 2002; 8: 1082-1086.
53. Ball DW, Azzoli CG, Baylin SB, et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci U S A 1993; 90: 5648-5652.
54. Gilks CB, Bear SE, Grimes HL, Tsichlis PN. Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein. Mol Cell Biol 1993; 13: 1759-1768.
55. Wallis D, Hamblen M, Zhou Y, et al. The zinc finger transcription factor Gfi1, implicated in lymphomagenesis, is required for inner ear hair cell differentiation and survival. Development 2003; 130: 221-232.
56. Travis WD, Colby TV, Corrin B, Shimosato, Y, Brambilla E. Histological Typing of Lung and Pleural Tumours (3rd edn). Springer-Verlag: Berlin, 1999; 21-24.
57. Colby TV, Koss MN, Travis WD. Morphological Diagnosis and Heterogeneity. Atlas of Tumor Pathology: Tumors of the Lower Respiratory Tract, 3rd Series. Armed Forces Institute of Pathology: Bethesda, MD, 1995; 135-143.
58. Churg A. The fine structure of large cell undifferentiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. Hum Pathol 1978; 9: 143-156.